Binds Oligosaccharide Structure Patents (Class 530/387.5)
  • Patent number: 11549102
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: January 10, 2023
    Assignee: University of Washington
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Patent number: 10611826
    Abstract: The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and/or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg/ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: April 7, 2020
    Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Philippe Paolantonacci, Abdessatar Chtourou
  • Patent number: 9796785
    Abstract: The purpose of the present invention is to provide a novel monoclonal antibody having high affinity and that strictly recognizes, as a sugar chain epitope, only a “Sia?2,6Gal?1,4GlcNAc (6?-Sialyl-LacNAc): CDw75” sugar chain structure, being a molecular target for diagnosis of the malignancy of tumors. An anti-CDw75 monoclonal antibody is provided that recognizes “CDw75” sugar chain structures but does not recognize similar sugar chain structures indicated by “Gal?1,4GlcNAc”, “Sia?2,3Gal?1,4GlcNAc”, or “Sia?2,6Gal?1,4Glc”, by using a glycolipid antigen bonding a carrier lipid compound “HOCH2CH(NH—CO—(CH2)22—CH3)—(CH2)9—CH3 (C12L)” developed by the inventors to a “CDw75” sugar chain. The obtained anti-CDw75 monoclonal antibody is an excellent detection drug for B-cell lymphoma, gastric cancer, or colorectal cancer, an excellent diagnostic agent for tumor malignancy, etc.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 24, 2017
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventor: Tetsuya Okuda
  • Patent number: 9592238
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 14, 2017
    Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Publication number: 20150147328
    Abstract: The present invention relates to a vaccine composition for preventing staphylococcus aureus infection containing, as an active ingredient, a ribitol-phosphate which has been modified only by a ?-configuration in N-Acetylglucosamine (GlcNAc), a repeating unit of the ribitol-phosphate, or a wall teichoic acid (WTA) containing the repeating unit. The composition according to the present invention contains a coupling motif (an epitope) for an anti-WTA antibody, and thus can be effectively used as a vaccine composition or to prevent staphylococcus aureus infection by generating anti-WTA antibody.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 28, 2015
    Applicants: MOGAM BIOTECHNOLOGY INSTITUTE, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Bok Luel Lee, Kurokawa Kenji, Dong-Jun Jung, Jang-Hyun An, Yu-Jin Jeon, Na Hyang Kim, Takahashi Kazue, Eunmi Kim, Dong Ho Ahn
  • Publication number: 20150140576
    Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 21, 2015
    Applicant: GLYKOS FINLAND OY
    Inventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
  • Publication number: 20150139998
    Abstract: The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 21, 2015
    Inventors: Johannes Huebner, Otto Holst, Christian Theilacker, Karolina Kruszynska, Stefan Geiss-Liebisch, Agnieszka Beczala
  • Publication number: 20150110781
    Abstract: The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 23, 2015
    Inventors: Enyun Shen, Shiqi Ren
  • Publication number: 20150093388
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 2, 2015
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20150086555
    Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Inventors: Ole Olsen, Christina L. Boozer
  • Publication number: 20150071854
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 12, 2015
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
  • Publication number: 20150056134
    Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Ritsuko SAWADA, Shu-Man SUN, Wolfgang SCHOLZ
  • Publication number: 20150050282
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Application
    Filed: June 20, 2014
    Publication date: February 19, 2015
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scientifique, Universite Paris Descartes
    Inventors: Laurence MULARD, Julien BOUTET, Catherine GUERREIRO, Farida NATO, Philippe SANSONETTI, Armelle PHALIPON
  • Patent number: 8957188
    Abstract: Monoclonal antibodies to carbohydrate antigens containing a terminal GalNAc?1-3Gal are provided. The antibodies of the present invention are found to specifically recognize GalNAc?1-3Gal with little cross-reactivity to other structurally similar antigens such as GalNAc?1-6Gal, blood group A, Forssman antigen and the Tn antigen on both solution assays and human tissue. Compositions comprising the monoclonal antibodies, as well as methods of diagnosis, treatment and prognostication are also provided.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: February 17, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Gildersleeve, Zhitao Li, Qian Li, Miriam Anver, Donna O. Butcher
  • Publication number: 20150023968
    Abstract: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula.
    Type: Application
    Filed: December 6, 2012
    Publication date: January 22, 2015
    Inventors: Samer Al-Murrani, Jeffrey Brockman
  • Publication number: 20140341909
    Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.
    Type: Application
    Filed: June 27, 2014
    Publication date: November 20, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventor: Vince Pozsgay
  • Publication number: 20140341908
    Abstract: The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 20, 2014
    Applicant: INSTITUTE FOR SYSTEMS BIOLOGY
    Inventors: Carrie M. ROSENBERGER, Alan ADEREM
  • Publication number: 20140328824
    Abstract: The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.
    Type: Application
    Filed: December 4, 2012
    Publication date: November 6, 2014
    Inventor: Angel Porgador
  • Publication number: 20140322730
    Abstract: An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position 516 is N and is glycosylated. The present invention also provides an antibody that binds specifically to the polypeptide, an isolated nucleic acid comprising a polynucleotide that encodes the polypeptide; a method for reducing BoNT/E toxicity in an animal; a method for identifying an agent that blocks or inhibits binding between BoNT/E and an SV2A or SV2B protein; a method for monitoring synaptic vesicle endo- or exocytosis, a method for specifically delivering a chemical entity to a cell which has a specific receptor to a BoNT toxin.
    Type: Application
    Filed: May 20, 2014
    Publication date: October 30, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Edwin R. Chapman, Min Dong
  • Publication number: 20140314742
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: October 15, 2013
    Publication date: October 23, 2014
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Patent number: 8852873
    Abstract: Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: October 7, 2014
    Assignee: DiabetOmics, LLC
    Inventor: Srinivasa R. Nagalla
  • Publication number: 20140294930
    Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.
    Type: Application
    Filed: August 3, 2012
    Publication date: October 2, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Victor Nizet, Nina van Sorge
  • Publication number: 20140288277
    Abstract: Methods and compositions are provided for studying and targeting RNA structures. In particular, antibodies and antibody fragments that contain an Fab were produced. Phage display libraries that were engineered to produce RNA-specific antibody and antibody fragments were made. Antibodies, or fragments thereof, that have at least one Fab that specifically binds tRNAiMet, the P4-P6 domain of Tetrahymena Group I intron, the glycine riboswitch from Vibrio Cholerae, or the glycine riboswitch from Fusobacterium Nucleatum were identified. The production of these RNA-specific antibodies and antibody fragments can be used to study the structure of the RNA as well as to treat diseases with known RNA targets. For example, an Fab specific to tRNAiMet was produced that can be used to treat cancer in subjects where tRNAiMet is overexpressed.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Jingdong Ye, Eileen Sherman, Jennifer Archer
  • Patent number: 8828676
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Publication number: 20140235473
    Abstract: The present Invention provides a method for diagnosing and/or prognosing Parkinson's disease dementia (PDD) comprising the step of detecting O-glycosylation. in a protein comprising a Ser/Thr motive, in particular Serpin A1, and/or the level of sialic acid on a protein comprising a Ser/Thr motive, in particular Serpin A1. Further, the present invention relates to a molecule for detecting O-linked glycomoieties in a protein comprising a Ser/Thr motive, in particular Serpin A1, and/or glycosylated i so forms of a Ser/Thr motive comprising protein, in particular Serpin A1, for use in the diagnosis and/or prognosis of Parkinson's disease dementia (PDD), Furthermore, the present invention relates to means for diagnosing and/or prognosing Parkinson's disease dementia (PDD) and a kit for diagnosing and/or prognosing Parkinson's disease dementia (PDD).
    Type: Application
    Filed: June 22, 2012
    Publication date: August 21, 2014
    Inventors: Markus Otto, Stefan Lehnert, Sarah Jesse, Olaf Jahn
  • Publication number: 20140234318
    Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.
    Type: Application
    Filed: March 24, 2014
    Publication date: August 21, 2014
    Applicant: GLYKOS FINLAND OY
    Inventors: Jari NATUNEN, Susann TENEBERG, Karl-Anders KARLSSON, Tero SATOMAA, Annamari HEISKANEN
  • Publication number: 20140234364
    Abstract: The present invention relates to the total chemical synthesis of the monosaccharide 35# (R??H), the disaccharide 36# (R??H; R??H), the trisaccharide 37# (R??H; R??H; R???H) and the tetrasaccharide 1# (R??H; R??H; R???H) of the following general formula wherein R represents —Y—NH2Y represents a linker R? is H or R? is H or R?? is H or of the lipopolysaccharide from Neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or the trisaccharide ?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by Neisseria meningitidis.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 21, 2014
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, You Yang, Chakkumkal Anish, Anika Reinhardt
  • Publication number: 20140193416
    Abstract: The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[a-L-Rhap-(1?3]-a-D-Glcp-(1?2)-a-D-Glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker L for conjugation to a carrier protein or for immobilization on a surface. Further aspects of the invention relate to advantageous methods for synthesizing said synthetic oligosaccharide and oligosaccharide-protein conjugate as well as to uses thereof, in particular as vaccines and diagnostic tools.
    Type: Application
    Filed: July 30, 2012
    Publication date: July 10, 2014
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
  • Publication number: 20140178365
    Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
    Type: Application
    Filed: October 10, 2013
    Publication date: June 26, 2014
    Applicant: SIALIX INC
    Inventors: Darius Ghaderi, Ana Paula Galvao da Silva, Jeffrey Behrens, Julie Hermann, Nancy Hurtado-Ziola
  • Patent number: 8758753
    Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: June 24, 2014
    Assignee: Centro de Inmunologia Molecular (CIM)
    Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
  • Publication number: 20140170114
    Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.
    Type: Application
    Filed: February 17, 2014
    Publication date: June 19, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: David Kaplan
  • Publication number: 20140170151
    Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.
    Type: Application
    Filed: February 11, 2014
    Publication date: June 19, 2014
    Inventors: A. Stewart CAMPBELL, Obadiah J. PLANTE
  • Publication number: 20140170150
    Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 19, 2014
    Applicant: The Governors of the University of Alberta
    Inventors: Christine SZYMANSKI, Harald NOTHAFT
  • Publication number: 20140161806
    Abstract: A specific antibody against a compound of formula (I) wherein X is O, NH, S, CH2; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicant: AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital)
    Inventors: Cristina Nativi, Lucio Toma, Barbara Richichi, Carlotta Lunghi
  • Publication number: 20140161793
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 12, 2014
    Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche Scientifique
    Inventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
  • Publication number: 20140127265
    Abstract: The present disclosure provides an isolated or purified guinea pig cytomegalovirus (GPCMV) Strain CIDMTR, glycoproteins from GPCMV Strain CIDMTR, and methods of use thereof.
    Type: Application
    Filed: October 21, 2013
    Publication date: May 8, 2014
    Inventor: MARK SCHLEISS
  • Patent number: 8691585
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: April 8, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
  • Publication number: 20140093504
    Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.
    Type: Application
    Filed: January 31, 2012
    Publication date: April 3, 2014
    Applicant: Her Majesty The Queen In Right Of Canada, as repre sented by the Minister of National Defence
    Inventors: Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei YIN, Scott J. Jager, John W. Cherwonogrodzky
  • Publication number: 20140086923
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicants: INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante et de la Recherche Medicale, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD - LYON 1
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Publication number: 20140044721
    Abstract: The present invention lies in the field of new cancer therapies, more precisely in the field of antiangiogenic compounds. It notably concerns anti-Gb3 antibodies having specific CDR sequences, as well as the use of anti-Gb3 antibodies not coupled to a therapeutic molecule in the treatment of diseases associated with angiogenesis, such as solid tumors.
    Type: Application
    Filed: February 7, 2012
    Publication date: February 13, 2014
    Applicants: INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE, UNIVERSITE DE NANTES
    Inventors: François Paris, Stephane Birkle, Ariane Desselle, Jacques Aubry, Marie-Hélène Gaugler, Denis Cochonneau, Tanguy Chaumette
  • Publication number: 20140010829
    Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.
    Type: Application
    Filed: November 15, 2011
    Publication date: January 9, 2014
    Applicants: The Gov't of the United States, as Represented by, The Secretary of Health and Human Services, DUKE UNIVERSITY
    Inventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
  • Patent number: 8617846
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 31, 2013
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • Publication number: 20130344104
    Abstract: The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the Clostridium difficile glycopolymer PS-II and a protein carrier. More specifically, the oligosaccharide is the hexasaccharide having the following formula (I) wherein R is a linker or spacer group. In a specific embodiment of the invention, R is (CH2)nNH2, with n being an integer from 2 to 50. The present invention also provides the use of said oligosaccharide and said oligosaccharide-protein conjugate for the treatment or prevention of a disease caused by the pathogen Clostridium difficile. In still further aspects, the present invention also provides a favourable method for preparing said oligosaccharide and said oligosaccharide-protein conjugate.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Inventors: Peter H. Seeberger, Matthias Oberli, Marie-Lyn Hecht
  • Publication number: 20130315958
    Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 28, 2013
    Inventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
  • Publication number: 20130309237
    Abstract: Described herein are antigen binding proteins that bind to pathogenic mycobacteria-derived Mannose-Capped Lipoarabinomannan (ManLAM) and methods and kits for using and making the antigen binding proteins. Also described herein are antigen binding proteins that bind to the alpha 1-2 linkage mannose caps of ManLAM, antigen binding proteins that bind to a mannose cap with up to three alpha 1-2 linked mannose residues, and antigen binding proteins that bind to LAM with a mannose sugar capping motif.
    Type: Application
    Filed: January 25, 2012
    Publication date: November 21, 2013
    Applicants: DSO NATIONAL LABORATORIES, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Paul Anthony Macary, Conrad En Zuo Chan, Brendon John Hanson, Markus R. Wenk
  • Publication number: 20130295099
    Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.
    Type: Application
    Filed: February 11, 2011
    Publication date: November 7, 2013
    Applicant: The Governors of the University of Alberta
    Inventors: Christine SZYMANSKI, Harald NOTHAFT
  • Publication number: 20130295100
    Abstract: The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.
    Type: Application
    Filed: November 21, 2011
    Publication date: November 7, 2013
    Applicant: OSPEDALE SAN RAFFAELE S.R.L.
    Inventors: Paolo Manunta, Lorena Citterio, Giovanni Guglielmo Landoni, Elena Giovanna Bignami, Elisabetta Messaggio
  • Publication number: 20130281317
    Abstract: Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans.
    Type: Application
    Filed: November 23, 2011
    Publication date: October 24, 2013
    Applicant: Allbert Einstein College of Medicine of Yeshiva University
    Inventors: Jonathan R. Lai, Alex Stewart
  • Publication number: 20130273074
    Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the treatment and prevention of disorders associated with inflammation of alimentary tract, such as human immunodeficiency virus (HIV) infection and ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: October 4, 2011
    Publication date: October 17, 2013
    Applicant: IMMURON LIMITED
    Inventors: Grant Thomas Rawlin, Zeil Rosenberg, Oren Fuerst
  • Publication number: 20130273097
    Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
    Type: Application
    Filed: June 4, 2013
    Publication date: October 17, 2013
    Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins